

Drugs and Aging, 2019

Supplement: Safety of Anti-Osteoarthritis Medications

Safety of symptomatic slow-acting drugs in osteoarthritis: outcomes of a systematic review and meta-analysis

Germain Honvo, Jean-Yves Reginster, Véronique Rabenda, Anton Geerinck, Ouafa Mkinsi, Alexia Charles, Rene Rizzoli, Cyrus Cooper, Bernard Avouac, Olivier Bruyère

ELECTRONIC SUPPLEMENTARY MATERIAL 2

A) Glucosamine sulfate

Figure 14: Forest plot displaying the results of the meta-analyses comparing gastrointestinal disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 15: Forest plot displaying the results of the meta-analyses comparing cardiac disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 16: Forest plot displaying the results of the meta-analyses comparing vascular disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 17: Forest plot displaying the results of the meta-analyses comparing nervous system disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 18: Forest plot displaying the results of the meta-analyses comparing dermatological disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed





Figure 19: Forest plot displaying the results of the meta-analyses comparing musculoskeletal and connective tissue disorders with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed



Renal and urinary disorders: Zero events with GS and placebo in all included studies.

Figure 20: Forest plot displaying the results of the meta-analyses comparing severe adverse events with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 21: Forest plot displaying the results of the meta-analyses comparing serious adverse events with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed





Figure 22: Forest plot displaying the results of the meta-analyses comparing dropouts due to adverse event with glucosamine sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed



B) Chondroitin sulfate

Figure 23: Forest plot displaying the results of the meta-analyses comparing gastrointestinal disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 24: Forest plot displaying the results of the meta-analyses comparing cardiac disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 25: Forest plot displaying the results of the meta-analyses comparing vascular disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 26: Forest plot displaying the results of the meta-analyses comparing nervous system disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 27: Forest plot displaying the results of the meta-analyses comparing dermatological disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 28: Forest plot displaying the results of the meta-analyses comparing musculoskeletal and connective tissue disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 29: Forest plot displaying the results of the meta-analyses comparing renal and urinary disorders with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 30: Forest plot displaying the results of the meta-analyses comparing severe adverse events with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 31: Forest plot displaying the results of the meta-analyses comparing serious adverse events with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed





Figure 32: Forest plot displaying the results of the meta-analyses comparing dropouts due to adverse events with chondroitin sulfate versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed



C) Avocado soybean unsaponifiables

Figure 33: Forest plot displaying the result of the meta-analysis comparing gastrointestinal disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 34: Forest plot displaying the result of the meta-analysis comparing cardiac disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 35: Forest plot displaying the result of the meta-analysis comparing vascular disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 36: Forest plot displaying the result of the meta-analysis comparing nervous system disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 37: Forest plot displaying the result of the meta-analysis comparing skin and subcutaneous tissue disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 38: Forest plot displaying the result of the meta-analysis comparing musculoskeletal and connective tissue disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 39: Forest plot displaying the result of the meta-analysis comparing renal and urinary disorders with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 40: Forest plot displaying the result of the meta-analysis comparing severe adverse events with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed




Figure 41: Forest plot displaying the result of the meta-analysis comparing serious adverse events with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed





Figure 42: Forest plot displaying the result of the meta-analysis comparing dropouts due to adverse events with avocado soybean unsaponifiables versus placebo in patients with OA: Analysis of studies with concomitant anti-OA medications allowed



D) Diacerein

Figure 43: Forest plot displaying the results of the meta-analyses comparing cardiac disorders with diacerein versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 44: Forest plot displaying the results of the meta-analyses comparing vascular disorders with diacerein versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 45: Forest plot displaying the results of the meta-analyses comparing musculoskeletal and connective tissue disorders with diacerein versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 46: Forest plot displaying the results of the meta-analyses comparing severe adverse events with diacerein versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed




Figure 47: Forest plot displaying the results of the meta-analyses comparing serious adverse events with diacerein versus placebo in patients with OA: Overall analysis and analyses of studies with and without concomitant anti-OA medication allowed

